Dutch precision fermentation company Vivici has received €12.5 million in funding from the European Innovation Council (EIC) Accelerator Program, which will be used to scale market access and supply of its Vivitein ingredient portfolio. The company was selected among 38 start-ups and SMEs in the latest funding round, with a total of roughly €90 million in grants allocated by the EIC.

Due to a tightening market for conventional whey protein supply, Vivici's innovative approach of producing proteins using microorganisms engineered to secrete dairy-identical proteins has positioned them favorably in the industry. With a recent Series A round raising €32.5 million and successful launches of their beta-lactoglobulin protein and lactoferrin in the US market, Vivici is well-poised for growth and expansion. Other companies receiving support in this round include French start-up MUMILK, working on infant nutrition ingredients through mammalian cell bioproduction under the NūmiMilk brand.

This funding from the EIC is a strong endorsement of Vivici's work in precision fermentation, allowing them to accelerate their efforts in turning their innovative technology into a commercial reality on a larger scale. CEO Stephan van Sint Fiet expressed gratitude for the support, highlighting the opportunity to deliver high-quality products to customers and consumers.